Johannes Gutenberg-Universität Mainz
- 6131/39-0
Esser, Stefan; Schoefer, Helmut; Hoffmann, Christian et al.
S1 Guidelines for the Kaposi SarcomaJOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. Bd. 20. H. 6. 2022 S. 892-903
Helbig, Doris; Ziemer, Mirjana; Dippel, Edgar et al.
S1-guideline atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS)JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. Bd. 20. H. 2. 2022 S. 235-243
Chakrabarty, Sagarika; Bui, Quyen; Badeanlou, Leylla et al.
S1P/S1PR3 signalling axis protects against obesity-induced metabolic dysfunctionADIPOCYTE. Bd. 11. H. 1. 2022 S. 69-83
Dippel, Edgar; Assaf, Chalid; Becker, Juergen C. et al.
S2k-Guidelines - Cutaneous lymphomas (ICD10 C82-C86): Update 2021JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. Bd. 20. H. 4. 2022 S. 537-554
Bitzer, M.; Voesch, S.; Albert, J. et al.
S3 Guideline: Diagnosis and Therapy of Biliary Carcinoma Short Version 2.00-June 2021, AWMF Register Number: 032-053OLZEITSCHRIFT FUR GASTROENTEROLOGIE. Bd. 60. H. 02. 2022 S. 219-238
Bitzer, M.; Voesch, S.; Albert, J. et al.
S3-Guideline - Diagnosis and Therapy of Biliary CarcinomaZEITSCHRIFT FUR GASTROENTEROLOGIE. Bd. 60. H. 02. 2022 S. E186-E227
Dam, Tien; Boxer, Adam L.; Golbe, Lawrence I. et al.
Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial (August, 10.1038/s41591-021-01455-x, 2021)NATURE MEDICINE. 2022
Wallace, Daniel J.; Atsumi, Tatsuya; Daniels, Mark et al.
Safety of belimumab in adult patients with systemic lupus erythematosus: Results of a large integrated analysis of controlled clinical trial dataLUPUS. Bd. 31. H. 13. 2022 S. 1649-1659
Lommatzsch, Marek; Suhling, Hendrik; Korn, Stephanie et al.
Safety of combining biologics in severe asthma: Asthma-related and unrelated combinationsALLERGY. Bd. 77. H. 9. 2022 S. 2839-2843
Tilch, Marie-Kristin; Robak, Tadeusz; Ghiggi, Chiara et al.
Safety of the Anti-CD19 antibody Tafasitamab in Long Term Responders from A Phase II Trial for Relapsed LymphomaCLINICAL LYMPHOMA MYELOMA & LEUKEMIA. Bd. 22. H. 4. 2022 S. 270-275